Foundayo vs. the Wegovy Pill:
The Two Oral GLP-1 Options, Compared

Why daily pills are a new development in GLP-1 therapy

Until late 2025, every approved GLP-1 receptor agonist for weight management in the United States required a weekly injection. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) had already transformed obesity medicine, producing weight loss of 15 to 22 percent in large clinical trials. For many patients, however, injections remained a barrier — whether due to needle aversion, travel logistics, refrigeration requirements, or simply the psychological weight of a weekly self-injection routine.

Two drugs have now changed that. On December 22, 2025, the FDA approved oral semaglutide 25 mg, marketed as the Wegovy pill, for chronic weight management. On April 1, 2026, the FDA approved orforglipron under the brand name Foundayo, making it the second oral GLP-1 option for obesity and the first one with no food or water restrictions at dosing time. The two drugs compete directly for the same population, but they are not the same medication, and the differences between them are clinically meaningful.

The two drugs at a glance

How each one works, and why the molecule type matters

Both medications activate GLP-1 receptors, producing the same physiological effects that make injectable GLP-1s effective: slowed gastric emptying, reduced appetite, improved insulin secretion, and lower post-meal glucose. The mechanism is the same. The molecule achieving it is fundamentally different — and that difference has practical consequences.

The Wegovy pill: same semaglutide, different delivery

The Wegovy pill contains semaglutide, the same active molecule in Ozempic and injectable Wegovy. The challenge of making a peptide drug work orally is that the gut normally destroys peptides before they reach the bloodstream. Novo Nordisk solves this by combining semaglutide with a chemical absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate), which creates a local pH change in the stomach lining that allows semaglutide to be absorbed directly through the stomach wall. This is why the pill must be taken on an empty stomach with minimal water: food dilutes the SNAC effect and significantly reduces absorption. The oral dose (25 mg) is far higher than the injectable dose (2.4 mg weekly) because only a fraction of the oral dose is absorbed.

Foundayo: a different kind of molecule entirely

Orforglipron is not a peptide. It is a small molecule — the same class of compound as most conventional medications, tablets, and capsules people take every day. Because orforglipron does not depend on a specific stomach environment for absorption, it can be taken at any time of day, with any amount of food or water, without restrictions. This flexibility is its most significant practical advantage over the Wegovy pill. The tradeoff is that orforglipron has a shorter track record than semaglutide, which has been in clinical use since 2017.

What clinical trials showed

Both drugs were evaluated in large Phase 3 randomized, double-blind, placebo-controlled trials published in the New England Journal of Medicine in September 2025. Critically, the two trials were not run head-to-head and no direct comparison trial exists as of May 2026. They enrolled different numbers of participants, ran for different durations, and used somewhat different reporting conventions. Any efficacy comparisons between the two are across separate trials with separate populations, and should be interpreted with that context firmly in mind.

Taking the trials at face value, the Wegovy pill produced somewhat higher average weight loss. A combined analysis published in Frontiers in Medicine (2025) noted that OASIS 4 showed mean weight loss of 13.6% versus 11.2% for ATTAIN-1, with 63% of OASIS 4 participants achieving at least 10% weight loss versus 54.6% in ATTAIN-1. The absolute difference is meaningful on a population level, though it does not tell any individual patient how they personally will respond.

Both medications produced clinically meaningful improvements beyond weight loss. OASIS 4 participants showed significant reductions in HbA1c, fasting glucose, CRP, triglycerides, and blood pressure. ATTAIN-1 participants showed reductions in waist circumference, non-HDL cholesterol, triglycerides, and systolic blood pressure. The cardiometabolic benefits appear directionally similar, though Wegovy also carries a specific FDA-approved cardiovascular outcomes indication based on the SELECT trial for adults with established cardiovascular disease, which Foundayo does not yet have.

How to take them: a practically important difference

This is where the two medications differ most significantly in everyday life. The administration requirements are not minor details: they directly affect adherence, which determines how well any medication works long-term.

For patients with predictable morning routines, the Wegovy pill's fasting requirement may not be a significant barrier. For shift workers, parents of young children, frequent travelers, or anyone whose mornings are unpredictable, the 30-minute fasting window can become a genuine adherence challenge. Foundayo removes that variable entirely.

Side effects

Both medications share the GLP-1 class side effect profile, dominated by gastrointestinal symptoms that are typically mild to moderate and peak during the dose escalation phase. Neither drug showed hepatic safety signals in their trial programs — worth noting given that liver toxicity led to the discontinuation of two earlier oral GLP-1 candidates from Pfizer.

Cost and access

As of May 2026, the self-pay starting price for both oral GLP-1 medications is approximately $149 per month. This is the starting-dose price — cost increases with higher doses, so the monthly out-of-pocket amount may be higher depending on where you are in the titration schedule. For context, injectable GLP-1 options start considerably higher: injectable Wegovy begins at approximately $199 per month and Zepbound at approximately $299 per month through manufacturer programs. The lower price point for oral options reflects an intentional access strategy from both Novo Nordisk and Eli Lilly, aimed at reaching patients without insurance coverage for obesity medications.

Insurance coverage for both drugs is evolving rapidly and varies significantly by plan, employer, and state. Foundayo is available through LillyDirect with free home delivery.

Medicare coverage is improving. Starting July 1, 2026, a program called the Bridge to Benefits will offer GLP-1 weight-loss medications to qualifying Medicare beneficiaries for $50 per month through December 31, 2027. Eligibility requirements apply — patients should verify their coverage directly with Medicare or their Part D plan.

Who might be better suited to each medication

There is no universally better option between these two drugs. The right choice depends on individual circumstances, medication history, lifestyle, and what matters most to a given patient. The following is a clinical framework, not a prescription. Your provider needs to assess your complete picture.

How pills compare to injectable GLP-1 medications

Both oral options produce less weight loss on average than the injectable versions of the same or related molecules. Injectable Wegovy (semaglutide 2.4 mg weekly) produced approximately 15 to 17 percent weight loss in the STEP trials. Injectable Zepbound (tirzepatide) produced 20 to 22 percent weight loss in the SURMOUNT trials. Oral semaglutide's 13.6% and Foundayo's 11.2% sit below those benchmarks.

Eli Lilly's CEO acknowledged this directly at launch, noting that Foundayo is not more effective than Zepbound but is more accessible and easier to fit into daily routines. For patients who will reliably take a daily pill but would not reliably take a weekly injection, a pill with 11 to 13 percent weight loss is more effective than an injection they stop using after two months. Adherence is the dominant variable in real-world outcomes.

Other oral GLP-1 medications in development

Foundayo and the Wegovy pill will not be the last oral GLP-1 options. Several other companies have pursued or are currently pursuing oral small-molecule GLP-1 agonists, with varied results. Here is where the most notable programs stand as of May 2026.

The Pfizer experience with both lotiglipron and danuglipron is an important cautionary note. Liver safety is a specific concern with oral small-molecule GLP-1 drugs because of how they are metabolized. Orforglipron is processed through the CYP3A4 hepatic pathway, which is why co-administration with strong CYP3A4 inhibitors requires monitoring. The FDA's post-approval request for additional liver safety data from Eli Lilly reflects the field's awareness of this issue, even though no hepatic signal was detected in the ATTAIN program of more than 4,500 participants.